Dear Editor,For patientswith epidermal growth factor receptor(EGFR)mutant non-small cell lung cancer(NSCLC),EGFR tyrosine kinase inhibitors(TKIs)are used as the first-line treatment[1,2].Despite initial therapeutic re...Dear Editor,For patientswith epidermal growth factor receptor(EGFR)mutant non-small cell lung cancer(NSCLC),EGFR tyrosine kinase inhibitors(TKIs)are used as the first-line treatment[1,2].Despite initial therapeutic responses,patients invariably experience disease progression due to acquired drug resistance[3].Resistance arises,in part,because a subset of cancer cells undergoes epithelial-mesenchymal transition(EMT)and remains viable despite exposure to EGFR TKI concentrations that eliminate the bulk population[4].The surviving cells can be re-sensitized to treatment by prolonged culture in the absence of EGFR TKIs,indicating a transient.展开更多
基金the Roswell Park Alliance Foundation(Taste of Life Award),the American Lung Association Lung Cancer Discovery Award LCD615335,S10OD010393-01the Roswell Park Cancer Center Support Grant P30 CA016056 that supports the Laboratory Animal Shared Resource and Translational Imaging Shared Resource utilized in this work.
文摘Dear Editor,For patientswith epidermal growth factor receptor(EGFR)mutant non-small cell lung cancer(NSCLC),EGFR tyrosine kinase inhibitors(TKIs)are used as the first-line treatment[1,2].Despite initial therapeutic responses,patients invariably experience disease progression due to acquired drug resistance[3].Resistance arises,in part,because a subset of cancer cells undergoes epithelial-mesenchymal transition(EMT)and remains viable despite exposure to EGFR TKI concentrations that eliminate the bulk population[4].The surviving cells can be re-sensitized to treatment by prolonged culture in the absence of EGFR TKIs,indicating a transient.
